- Home
- MYGN vs VIR Comparison
MYGN vs VIR Comparison
Compare MYGN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- VIR
- Stock Information
- Founded
- MYGN 1991
- VIR 2016
- Country
- MYGN United States
- VIR United States
- Employees
- MYGN N/A
- VIR N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- MYGN Health Care
- VIR Health Care
- Exchange
- MYGN Nasdaq
- VIR Nasdaq
- Market Cap
- MYGN 744.7M
- VIR 706.4M
- IPO Year
- MYGN 1995
- VIR 2019
- Fundamental
- Price
- MYGN $5.34
- VIR $5.65
- Analyst Decision
- MYGN Hold
- VIR Strong Buy
- Analyst Count
- MYGN 15
- VIR 8
- Target Price
- MYGN $15.14
- VIR $30.25
- AVG Volume (30 Days)
- MYGN 1.3M
- VIR 1.2M
- Earning Date
- MYGN 08-05-2025
- VIR 07-31-2025
- Dividend Yield
- MYGN N/A
- VIR N/A
- EPS Growth
- MYGN N/A
- VIR N/A
- EPS
- MYGN N/A
- VIR N/A
- Revenue
- MYGN $831,300,000.00
- VIR $20,861,000.00
- Revenue This Year
- MYGN N/A
- VIR N/A
- Revenue Next Year
- MYGN $6.68
- VIR $0.62
- P/E Ratio
- MYGN N/A
- VIR N/A
- Revenue Growth
- MYGN 7.38
- VIR N/A
- 52 Week Low
- MYGN $3.81
- VIR $4.32
- 52 Week High
- MYGN $29.30
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- MYGN 50.85
- VIR 57.21
- Support Level
- MYGN $4.90
- VIR $5.20
- Resistance Level
- MYGN $5.83
- VIR $6.23
- Average True Range (ATR)
- MYGN 0.28
- VIR 0.30
- MACD
- MYGN 0.04
- VIR 0.07
- Stochastic Oscillator
- MYGN 54.21
- VIR 56.06
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.